Loss of Collagen-receptor DDR1 Delays Renal Fibrosis in Hereditary Type IV Collagen Disease
Overview
Molecular Biology
Authors
Affiliations
Alport syndrome is a hereditary type IV collagen disease leading to progressive renal fibrosis, hearing loss and ocular changes. End stage renal failure usually develops during adolescence. COL4A3-/- mice serve as an animal model for progressive renal scarring in Alport syndrome. The present study evaluates the role of Discoidin Domain Receptor 1 (DDR1) in cell-matrix interaction involved in pathogenesis of Alport syndrome including renal inflammation and fibrosis. DDR1/COL4A3 Double-knockouts were compared to COL4A3-/- mice with 50% or 100% expression of DDR1, wildtype controls and to DDR1-/- COL4A3+/+ controls for over 6years. Double-knockouts lived 47% longer, mice with 50% DDR1 lived 29% longer and showed improved renal function (reduction in proteinuria and blood urea nitrogen) compared to animals with 100% DDR1 expression. Loss of DDR1 reduced proinflammatory, profibrotic cells via signaling of TGFbeta, CTGF, NFkappaB and IL-6 and decreased deposition of extracellular matrix. Immunogold-staining and in-situ hybridisation identified podocytes as major players in DDR1-mediated fibrosis and inflammation within the kidney. In summary, glomerular epithelial cells (podocytes) express DDR1. Loss of DDR1-expression in the kidney delayed renal fibrosis and inflammation in hereditary type IV collagen disease. This supports our hypothesis that podocyte-matrix interaction via collagen receptors plays an important part in progression of renal fibrosis in Alport disease. The blockade of collagen-receptor DDR1 might serve as an important new therapeutic concept in progressive fibrotic and inflammatory diseases in the future.
Discoid Domain Receptors Signaling in Macrophages-Mediated Diseases.
Ma Y, Gong H, Cheng L, Zhang D Int J Gen Med. 2025; 18:907-926.
PMID: 39990299 PMC: 11847422. DOI: 10.2147/IJGM.S487093.
Exploration of Gene Therapy for Alport Syndrome.
Zhao Y, Zheng Q, Xie J Biomedicines. 2024; 12(6).
PMID: 38927366 PMC: 11200676. DOI: 10.3390/biomedicines12061159.
Progress in therapeutic targets on podocyte for Alport syndrome.
Zheng Q, Gu X, He J, Xie J J Transl Int Med. 2024; 12(2):129-133.
PMID: 38812923 PMC: 11135632. DOI: 10.2478/jtim-2024-0005.
Mariadoss A, Wang C Int J Mol Sci. 2023; 24(19).
PMID: 37834343 PMC: 10573612. DOI: 10.3390/ijms241914895.
iPSC-derived type IV collagen α5-expressing kidney organoids model Alport syndrome.
Hirayama R, Toyohara K, Watanabe K, Otsuki T, Araoka T, Mae S Commun Biol. 2023; 6(1):854.
PMID: 37770589 PMC: 10539496. DOI: 10.1038/s42003-023-05203-4.